Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib for Remaining GGN in EGFR+ Stage IB-IIIA Lung Adenocarcinoma
NCT05528458Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Sep 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in lung adenocarcinoma, sponsored by Samsung Medical Center. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05528458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528458.